References
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
- American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society, 2015. Available at: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf [Last accessed February 2015]
- Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Myeloma. National Cancer Institute, 2013. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html [Last accessed February 2015]
- Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73
- Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063-73
- Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014;32:587-600
- Rodríguez MRL, Combariza J, Casas CP, et al. First line therapy for patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation: a systematic review and meta-analysis (hemo-oncol group study). Appl Cancer Res 2012;32:122-41
- Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011;17:1253-63
- Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
- Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist 2007;12:664-89
- Velcade [package insert]. Cambridge (MA): Millennium Pharmaceuticals, 2014
- Thalomid [package insert]. Summit (NJ): Celgene Corp, 1998
- Revlimid [package insert]. Summit (NJ): Celgene Corp, 2005
- Kyprolis [package insert]. South San Francisco (CA): Onyx Pharmaceuticals, 2012
- Pomalyst [package insert]. Summit (NJ): Celgene Corp, 2013
- San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib–melphalan–prednisone versus melphalan–prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013;31:448-55
- Facon T, Mary J, Hulin C, et al. Major superiority of melphalan–prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 2006;106:230a
- Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine–doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9
- Benboubker L, Dimopoulos MA, Dispenzieri A, et al. FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906-17
- Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375-82
- Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-9
- Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematol Am Soc Hematol Educ Program 2007;317-23
- Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068-74
- Kleber M, Ihorst G, Terhorst M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 2011;1:e35
- Gay F, Palumbo A. Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol 2010;27(Suppl 1):S43-52
- Burnette BL, Dispenzieri A, Kumar S, et al. Treatment trade-offs in myeloma: a survey of consecutive patients about contemporary maintenance strategies. Cancer 2013;119:4308-15